β3 Subunits Promote Expression and Nicotine-Induced Up-Regulation of Human Nicotinic α6* Nicotinic Acetylcholine Receptors Expressed in Transfected Cell Lines

Prem Tumkosit, Alexander Kuryatov, Jie Luo, and Jon Lindstrom

Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, Pennsylvania

Received June 1, 2006; accepted July 11, 2006

ABSTRACT

Nicotinic acetylcholine receptors (AChRs) containing α6 subunits are typically found at aminergic nerve endings where they play important roles in nicotine addiction and Parkinson’s disease. α6* AChRs usually contain β3 subunits. β3 subunits are presumed to assemble only in the accessory subunit position within AChRs where they do not participate in forming acetylcholine binding sites. Assembly of subunits in the accessory position may be a critical final step in assembly of mature AChRs. Human α6 AChR subtypes were permanently transfected into human tsA201 human embryonic kidney (HEK) cell lines. α6β2β3 and α6β4β3 cell lines were found to express much larger amounts of AChRs and were more sensitive to nicotine-induced increase in the amount of AChRs than were α6β2 or α6β4 cell lines. The increased sensitivity to nicotine-induced up-regulation was due not to a β3-induced increase in affinity for nicotine but probably to a direct effect on assembly of AChR subunits. HEK cells express only a small amount of mature α6β2 AChRs, but many of these subunits are on the cell surface. This contrasts with Xenopus laevis oocytes, which express a large amount of incorrectly assembled α6β2 subunits that bind cholinergic ligands but form large amorphous intra-cellular aggregates. Monoclonal antibodies (mAbs) were made to the α6 and β3 subunits to aid in the characterization of these AChRs. The α6 mAbs bind to epitopes C-terminal of the extracellular domain. These data demonstrate that both cell type and the accessory subunit β3 can play important roles in α6* AChR expression, stability, and up-regulation by nicotine.

Nicotinic acetylcholine receptors (AChRs) are composed of five homologous subunits (Lindstrom, 2000; Sine and Engel, 2006). Heteromeric neuronal AChRs contain two ACh binding sites formed by the interfaces of α2, α3, α4, or α6 subunits with β2 or β4 subunits. The fifth “accessory” subunit does not participate in forming an ACh binding site but contributes to the channel lining and influences assembly, transport, and function of AChRs. The accessory position is often occupied by β2 or β4 subunits, but α4 can also assemble there (Kuryatov et al., 2005). β3 and α5 can assemble only in this position. AChRs containing α6 subunits (α6* AChRs) comprise minor subtypes selectively localized in the endings of aminergic neurons (Zoli et al., 2002; Champniaux et al., 2003; Gotti et al., 2005b). α6* AChRs contribute to nicotine-stimulated dopamine release from striatal synaptosomes (Azam and McIntosh, 2005), are selectively lost in animal models of Parkinson’s disease, and are potential targets for Parkinson’s disease therapy (Quik and McIntosh, 2006). α6* AChRs are the major non-α4* AChR expressed in the optic tract (Gotti et al., 2005b). β3 subunits are usually found in α6* AChRs, and knockout of β3 reduces but does not eliminate expression of α6* AChRs (Gotti et al., 2005a).

Nicotine up-regulates the amount of brain AChRs (Flores et al., 1992). Nicotine treatment has been reported to both increase (Parker et al., 2004) and decrease the amount of brain α6* AChRs (Lai et al., 2005; McCallum et al., 2006; Mugnaini et al., 2006). In transfected HEK cell lines, nicotine applied overnight increases the amount of human α3β2 and α4β2 AChRs but not α3β4 or α4β4 AChRs, primarily by acting as a pharmacological chaperone to promote assembly of AChRs (Wang et al., 1998; Kuryatov et al., 2005; Sallette et al., 2005; Corringer et al., 2006). Putative assembly intermediates the size of α4β2α4β2 tetramers have been identified that could assemble with accessory subunits in a final step to produce mature AChRs (Kuryatov et al., 2005). Nic-
otope also contributes to up-regulation by increasing the lifetime of surface membrane AChRs (Kuryatov et al., 2005). Nicotine applied to transfected HEK cell lines for 5 days up-regulated rat AChRs containing α2, α3, or α4 in combination with β2 or β4 subunits (Xiao and Keller, 2004).

It has been challenging to express α6 AChRs (Gerzanich et al., 1997). In Xenopus laevis oocytes, human α6β4 AChRs were functional, and α6β4β3 AChRs were expressed at a higher level (Kuryatov et al., 2000). Although coexpression of α6 and β2 produced abundant ACh binding sites, they were on amorphous aggregates within the oocytes. Chimeric subunits with the extracellular domain of α6 and the remainder of either α3 or α4 subunits assembled efficiently with either β2 or β4 subunits in oocytes (Kuryatov et al., 2000). In human BOSC 23 cells, chicken α6β2 were AChRs expressed at a lower level than α4β4 (Fucile et al., 1998). Attempts to express human α6β2, α6β3β3, αβ4, and α6β4β3 AChRs in transfected SH-EPI cell lines were unsuccessful, but the α6β4β3α5 subunit combination exhibited cholinergic ligand binding (Grinevich et al., 2005). Chimeric subunits with the extracellular domain of α6 and the remainder of α4 formed functional AChRs in HEK cell lines (Evans et al., 2003). α6 subunits are closely related in sequence to α3 and α4 subunits, and α6β3 subunits are closely related to α5 subunits (Lindstrom, 2000; Neove et al., 2002). Permanently transfected HEK tsA201 cells have been used to express human α3β3 and α4β6 AChRs (Wang et al., 1998; Nelson et al., 2001; Kuryatov et al., 2005). α3β2 AChRs assembled efficiently in X. laevis oocytes (Wang et al., 1996; Gerzanich et al., 1998), but in HEK cells they do not assemble efficiently unless up-regulation is induced by nicotine or culture at low temperatures (Wang et al., 1998). Coexpression in HEK cells of α3β3 with α5 increases expression, but coexpression of α3β4 with α5 somewhat decreases expression (Wang et al., 1998). In oocytes, α5 subunits alter desensitization, pharmacology, and Cα2+ permeability of α3 AChRs (Gerzanich et al., 1998), so it might be expected that β3 subunits would similarly have substantial effects on α6 AChRs.

Here, we report the production of stably transfected tsA201 HEK lines expressing four subtypes of human α6 AChRs and their initial characterization. Expression of β3 with either α6β2 or α6β4 subunit combinations increased the amount of AChRs expressed and increased their sensitivity to up-regulation by nicotine. mAbs were made to human α6 and β3 subunits to aid in the characterization of these AChRs.

Materials and Methods
cDNAs. Human α6, β2, and β4 cDNAs were cloned in this laboratory as described previously (Anand and Lindstrom, 1990; Gerzanich et al., 1997; Kuryatov et al., 2000). Human β3 was obtained from Christopher Grantham (Janssen Research Foundation, Beerse, Belgium) and subcloned into pcDNA 3.1/Zeo (+) for transfection. α6 was subcloned into pE6/βlasticidin (+), β2 and β4 were separately cloned into pRc-CMV/Geneticin (+). All vectors were obtained from Invitrogen (Carlsbad, CA).

Cell Line Culture and Transfection. Human embryonic kidney tsA201 cell lines (Margolskee et al., 1993) were maintained in Dulbecco's modified Eagle's medium (DMEM, high glucose; Invitrogen) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT), 100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine at 37°C, 5% CO2 at saturating humidity in a water jacket incubator. HEK cells were transfected using the FuGENE 6 DNA transfection kit (Roche Diagnostics, Indianapolis, IN), according to the manufacturer's instructions, with human α6 (pE6/βlasticidin), human β2 (pRc-CMV/Geneticin (+)), or human β4 (pRc-CMV/Geneticin (+)). α6β2 was created by transfecting HEK cells with α6 and β2 cDNAs. α6β4 was created by transfecting HEK cells with α6 and β4 cDNAs. Selective pressure for cells containing α6 was applied with 5 μg/ml blasticidin starting 72 h after transfection. β2 and β4 cell lines were similarly selected with 600 μg/ml G418 (Genticin), α6β2 and α6β4 AChRs were assayed for expression and screened by [3H]epibatidine binding. Stably transfected α6β4 and α6β2 lines were cotransfected with human β3 (pcDNA 3.1/Zeocin (+)) to produce α6β4β3 and α6β2β3 AChRs. Selective pressure for cell lines containing β3 was applied using 500 μg/ml Zeocin starting 72 h after transfection. AChRs containing β3 were selected for high expression based on liquid phase radioimmunoassays. β3-transfected cell lines were plated in serial dilution on Costar 96-well plates (Corning Life Sciences, Acton, MA). Surviving colonies were plated individually to Costar 35-mm culture plates and then grown to confluence. Cells were detached with ice-cold DMEM and extracted as described above into a 1.5-ml microcentrifuge tube. AChRs were incubated with 2.5 nM [3H]epibatidine and 5 μl of β3 antisera, acquired from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), for 1 to 2 h at room temperature. AChRs were precipitated by secondary antibody incubation with rabbit anti-goat antisera for 1 to 2 h at room temperature and then pelleted at 13,000g for 10 min. Pellets were washed three times with 1 ml of 0.5% Triton X-100 in PBS + 10 mM NaN3 to remove excess radioligand. Washing solution was aspirated from the pellet before adding 50 μl of 0.1 N NaOH to solubilize the pellet. One milliliter of Optiphase SuperMix (PerkinElmer Life and Analytical Sciences, Boston, MA) was added to each sample. Samples with scintillation fluid were set on rotation for 1 h at room temperature before counting in a 1450 Microbeta Trilux liquid scintillation and luminescence counter (PerkinElmer Life and Analytical Sciences).

Membrane Fraction [3H]Epibatidine Binding. To assess relative expression levels across α6 containing AChR types expressed in HEK cells, stably transfected HEK cells were grown to confluence on Costar 35-mm tissue culture plates (approximately 106 cells/plate) and then detached by ice-cold DMEM and collected by centrifugation at 500g. Cells were washed once with 1 ml of buffer A (50 mM NaPO4, pH 7.5, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 5 mM benzamidine, 15 mM iodoacetamide, and 2 mM phenylmethylsulfonyl fluoride), pelleted by centrifugation at 13,000g, and then resuspended in buffer A. Cells in buffer A were incubated with 2 nM [3H]epibatidine for 30 min at room temperature with agitation. Cell membrane fractions were washed three times with PBS + 10 mM NaN3 on glass filters (GF/P, Whatman, Maidstone, UK) pretreated with 1% polyethyleneimine for 1 h and dried on blotting paper. Filters containing AChRs bound to radioligands were counted in 1.5-ml microcentrifuge tubes using 1 ml of Optiphase SuperMix scintillation fluid in a 1450 Microbeta Trilux liquid scintillation counter (PerkinElmer Life and Analytical Sciences). Results were standardized to the wet weight of the cells after the first wash in buffer A.

Previously Used Antisera and Monoclonal Antibodies. A rat antiserum to bacterially expressed α6 subunit sequences (excluding the transmembrane domains) was raised as described by Kuryatov et al. (2000). The rat mAb 210 binds to the main immunogenic region on native α1, α3, and α5 (Lindstrom, 2000) and β3 (A. Kuryatov and J. Lindstrom, unpublished data). The rat mAb 295 binds to the extracellular surface of AChR β2 subunits when they are assembled with α subunits (Lindstrom, 2000; Kuryatov et al., 2005). The mouse mAb 337 was raised to bacterially expressed human β4 subunit large cytoplasmic domain (Nelson et al., 2001).

Preparation of New mAbs. Human α6 and β3 subunits lacking the transmembrane domains of these subunits were constructed in the pET-26b (+) vector (Novagen, Madison, WI) and expressed in bacteria. α6 subunits were expressed in oocytes and extracted with
AChR Extraction from HEK Cells with Triton X-100. HEK cells expressing AChRs were grown in Costar 10- or 15-cm plates and then up-regulated by exposure to 100 μM nicotine overnight at 37°C. Cells were detached using 5 or 10 ml of ice-cold DMEM and then collected via centrifugation at 500g. DMEM was aspirated from the pellet. Cells were suspended with 1 ml of buffer A and then transferred to a 1.5-ml Eppendorf microcentrifuge tube and collected via centrifugation at 13,000g for 15 min at 4°C. Buffer A was aspirated from the pellets, which were then weighed. AChRs were extracted with 3 volumes of the pellet weight using buffer C (buffer A with 2% Triton X-100). The suspension was gently rotated for 1 h at room temperature. Cell debris was pelleted by centrifugation at 13,000g for 15 min at 4°C. Supernatant containing AChRs in Triton X-100 was removed to new 1.5-ml centrifuge tubes and used immediately, keeping samples at 0–4°C.

Western Blots. AChRs were extracted with 2% Triton X-100 as described above from either HEK cell lines or X. laevis oocytes expressing either α2β2, chimeric α6/α3 β2, or chimeric α3/α6 β2 AChRs. Samples were electrophoresed in precast 10% polyacrylamide Tris-glycine gels (Novex, San Diego, CA) under reducing conditions. Western transfer was done using a semidyod electroblocting chamber (Semi-Phor; Hoeffer, San Francisco, CA) to Trans-Blot Medium polyvinylidene difluoride membrane (Bio-Rad). Blots were quenched with 5% Carnation dried milk in 0.5% Triton X-100 in PBS, 10 mM NaN3. mAbs were used as indicated at 1:1000 dilution in milk blocking solution. Blots were probed overnight at 4°C on a shaker followed by three washes with 0.5% Triton X-100 in PBS, 10 mM NaN3. Blots were then incubated with 2 nM [2H]-goat anti-mouse IgG (specific activity 2.5 × 1018 cpm/mole) overnight on a shaker at 4°C followed by three washes with TPBS. Autoradiography was done at ~50°C with Kodak BioMax film using a Kodak MS screen (Eastman Kodak) for the indicated time periods.

Agonist Binding on Fixed Cells. Cells were plated onto Costar 96-well white with clear bottom plates and grown to 70% confluence. Nicotine was added to induce up-regulation of AChRs. Cells were incubated overnight at 37°C. Cells grown to confluence were exposed to 1 volume of 10% formalin added directly to the growth medium for 1 h at room temperature to fix the cells to the wells. Cells were washed free of agonist and formalin with 200 μl of PBS + 10 mM NaNO9 three times and stored at 4°C with 1 volume of PBS-NaNO9 until use. Agonists were applied at indicated concentrations with [3H]epibatidine at 2 nM. Binding was conducted at room temperature for 2 h with gentle agitation. Plates were again washed to remove unbound ligands as described above. [3H]Epibatidine was eluted from the AChRs by 50 μl of 0.1 N NaOH. Then, 200 μl of Optiphase SuperMix (PerkinElmer Life and Analytical Sciences) scintillation fluid was added to each well. Plates were then shaken at room temperature for 1 to 2 h before scintillation counting. Comparison of the maximum number of epibatidine binding sites in all four cell lines after up-regulation with nicotine revealed that in fixed cells 93 ± 7% of the binding sites observed in membrane fragments were detected on fixed cells. Binding to fixed cells was faster and easier than using membrane fragments and avoided variation as a result of cells detaching during washing, which occurred without fixation.

Sucrose Density Gradients. A linear gradient maker was loaded with 5.7 ml each of 5 and 20% sucrose in 0.5% Triton X-100 to construct an 11.4-ml, linear 5 to 20% sucrose gradient. Gradients were built in Quick-Seal centrifuge tubes (Beckman Coulter, Inc., Fullerton, CA) (15 × 51 mm). Then, 400 μl of cell extract was combined with 2 μl of extract of the electric organ from Torpedo californica (~1 μM α-bungarotoxin binding sites) for an internal size marker and loaded onto the top of each gradient. Gradients were centrifuged at 40,000 rpm for 16 h at 4°C in an XL-90 ultracentrifuge using an SW-4I rotor (Beckman Coulter, Inc.). After ultracentrifugation, the tubes were punctured, and fractions were collected from the bottom into microtubes Immulon Flat-bottomed 48Wells (Thermo Electron Corporation, Waltham, MA) using a fraction collector set to collect 10 drops per well (approximately 150 μl/well). The
96-well Immulon 4HBX plates were coated with mAb 295 to bind AChRs containing β2 or with mAb 338 to bind AChRs containing β4. Fractions were bound to their respective antibody overnight at 4°C with gentle agitation. After incubation, 30 µl from each fraction was transferred onto an Immulon plate coated with mAb 210 to bind Torpedo californica AChRs, and 70 µl of 2% Triton X-100 in buffer A was added. Solid phase radioimmunoassays were probed for 2 h at room temperature with agitation with 2 nM 125I-a-bungarotoxin to detect T. californica AChR binding on mAb 210 plates, or with 2 nM [3H]epibatidine to detect α6 AChR binding on mAb 295 or mAb 338 plates. Then, plates were washed three times with TPBS. Radioligand was dissociated by denaturing the samples with 50 µl of 0.1 N NaOH and transferred for counting into Costar 96-well white-walled plates containing 200 µl of Optiphase SuperMix.

**Determining β3 Incorporation.** α6β2 and β3β4 cell lines were extracted as described above using Triton X-100 in buffer A. Extracts were aliquoted into different sets for solid phase immunoprecipitation, total [3H]epibatidine binding, and mAb 210 agarose resin depletion. Sets aliquoted for mAb 210 agarose resin depletion were incubated with 20 µl of agarose resin coated with mAb 210 in a total volume of 100 µl along with 2 nM [3H]epibatidine. These samples were incubated overnight at 4°C with constant agitation. Supernatant fluid was collected from samples after 5000g centrifugation for 5 min, and then AChRs were precipitated with mAb 338. All samples were denatured with 50 µl of 0.1 N NaOH for 5 min and then shaken with 1 ml of Optiphase SuperMix for 2 h. β3 incorporation was calculated by the difference between the total and depleted samples over the total binding.

**Binding of [3H]Epibatidine to Cells.** Cells expressing α6β4 AChRs were grown in media as described above on 35-mm dishes. One day before assay, nicotine was added into the growth media at a final concentration of 10 µM for β3-containing cells and 100 µM for other cells. Binding to living cells attached to 35-mm plates was done in DMEM at 4°C for only 15 min with 1 nM [3H]epibatidine to minimize ongoing up-regulation and penetration of quaternary amines inside the cells. To determine the internal pool of epibatidine binding sites, 1 mM of the membrane-impermeable quaternary amine methylcarbamylcholine was added together with 1 nM [3H]epibatidine to inhibit binding to cell surface AChRs. Nonspecific labeling (around 1% of total) was determined by incubation with 100 µM nicotine and subtracted from total binding. After incubation, the cells were detached using 1 ml of ice-cold PBS with 5 mM EDTA and washed three times with 1 ml of ice-cold PBS by centrifugation (5 min at 500g) in Eppendorf tubes. The washed pellets were dissociated with 100 µl of 0.1 M NaOH, and bound radioactivity was determined in the same tubes using the scintillation counter with 1 ml per tube of scintillation fluid.

**Results**

**Construction of Stably Transfected tSA201 HEK Cell Lines Expressing α6β2, α6β2β3, α6β4, and α6β4β3 AChRs.** First α6β2 and α6β4 lines were established. Then, these lines were transfected with β3 to produce lines expressing α6β2β3 and α6β4β3 AChRs.

Total amounts of AChRs expressed were measured by [3H]epibatidine binding to cell membrane fractions (Fig. 1A). Expression of α6β2 AChRs (45 fmol/mg protein) was very low compared with α3β2 (200 fmol/mg; Wang et al., 1998) or α4β2 AChR HEK cell lines (900 fmol/mg; Kuryatov et al., 2005). Coexpression with β3 doubled the amount of AChR, much as coexpression with α5 doubled the amount of α3β2 AChRs (Wang et al., 1998). α6β4 expression was twice that of α6β2. Likewise, α3β4 expression in a HEK line exceeded α3β2 expression by 4-fold (Wang et al., 1998). The increased expression of β4-containing compared with β2-containing AChRs reflects less efficient assembly of β2 subunits as a result of a microdomain near the ACh binding site (Sallette et al., 2004) and results in increased sensitivity of β2-con-
taining AChRs to the molecular chaperone effects of nicotine, which selectively promotes increased assembly of β2-containing AChRs (Wang et al., 1998; Kuryatov et al., 2005; Fig. 1). Coexpression with β3 increased α6β4 expression a further 6-fold. By contrast, coexpression of α5 with α3β4 decreased expression by 30% (Wang et al., 1998).

Incubation with 100 μM nicotine overnight increased the amount of α6* AChRs (Fig. 1A). This increased α6β2 AChRs 4-fold, α6β2β3 AChRs 3.3-fold, α6β4 AChRs 3.2-fold, and α6β4β3 AChRs 1.5-fold. At the same time, up-regulation significantly increased surface expression in β2-containing cells (Fig. 1B). After up-regulation a greater fraction of the AChRs was found inside the cells (Fig. 1C). This was also observed after nicotine-induced up-regulation of α4β2 AChRs (Kuryatov et al., 2005). Nicotine acts as a molecular chaperone to rapidly promote assembly of new α4β2 AChRs in the endoplasmic reticulum (Kuryatov et al., 2005; Sallette et al., 2005; Corringer et al., 2006). Transport of α4β2 AChRs to the surface through the Golgi apparatus for modification of glycosylation may be a rate-limiting step in surface expression. Similar processes may occur with α6* AChRs.

The time course of up-regulation by 100 μM nicotine was similar for all of the cell lines (Fig. 2). Up-regulation was half complete within 3 h and close to maximal by 24 h. This is similar to the kinetics of up-regulation of α3β2 and α4β2 AChRs in tsA201HEK cell lines (Wang et al., 1998; Kuryatov et al., 2005).

Raising mAbs to α6 and β3 Subunits. Mouse mAbs were raised to bacterially expressed human α6 and β3 subunits. Those mAbs that cross-reacted between subunits by dot blots of bacterially expressed subunits were eliminated, leaving six mAbs to α6 and one to β3, which were subunit-specific by this criterion (Fig. 3A). mAb 376 reacted only on blots with denatured β3, not with native AChRs. The mAbs to α6 also reacted on Western blots with α6 subunits from AChRs expressed in HEK cell lines and showed no cross-reaction with α3, α4, β2, or β4 subunits of AChRs expressed in these cell lines (Fig. 3B). mAb 349 was the best for use on Western blots.

The relative amounts of α6 subunits in the four cell lines were compared by Western blotting (Fig. 3C). The α6β2 cell line expressed few native AChRs (Fig. 1A) and correspondingly contained few α6 subunits (Fig. 3C). Thus, there were not large pools of unassembled α6 subunits in the α6β2 line. The fact that transfection with β3 resulted in a greatly increased amount of α6 as seen in the α6β2β3 cell line suggests that unassembled α6 subunits and α6β2 AChRs turn over rapidly and that the presence of β3 subunits permits the formation of α6β2β3 AChRs, which are much more stable and therefore much more α6 accumulates.

The transmembrane orientation of the epitopes of the α6 mAbs was determined by Western blots (Fig. 3D). All six mAbs to α6 on Western blots recognized a chimera (α6β3) with the extracellular domain of α3 and the remainder of α6, but not a chimera (α6β3) with the extracellular domain of α6 and the remainder of α3 (Fig. 3D). This indicates that the epitopes recognized by the mAbs are located C-terminal of the extracellular domain in the α6 subunit.

The six mAbs to bacterially expressed (denatured) α6 also immunoprecipitate native human α6 AChRs, with mAbs 338, 350, and 351 being the most potent (Table 1). Three of these mAbs also cross-react weakly with AChRs from rat brains. This was tested using high (25 μg) amounts of mAbs in a 200-μl reaction mix containing 0.2 nM [3H]epibatidine—labeled rat brain AChRs precipitable by mAb 295 to β2 subunits. Of these AChRs, 4% were bound by mAb 350, and approximately 0.25% was bound by mAbs 338 and 351. Immunoadsorption demonstrated that β3 subunits were incorporated into α6 AChRs (Fig. 4), as would be expected from the large increase of expression in the presence of β3 (Fig. 1). The putative main immunogenic region (MIR) sequence 66-76 of human α6 subunits (KWNPDDYGGV/K) is closely related to sequences on human α3 (KWNPDDYGGV/K), α5 (RNPNDDYGG/IK), and β3 (RNPNDDYGG/II). mAb 210 was made to muscle type AChRs, competes for binding to them with other mAbs to the MI, and also binds to denatured α1 (Lindstrom, 2000). In addition, it binds very well to native human α3 AChRs (Wang et al., 1998), but it does not bind well to denatured α3. mAb 210 also binds to native but not denatured human α5 (Kuryatov et al., 1997). mAb 210 exhibited low affinity for direct immunoprecipitation of α6β2β3 or α6β4β3 AChRs, but mAb 210 coupled to agarose efficiently adsorbed α6β2β3 and α6β4β3 AChRs. It did not bind α6β2 or α6β4 AChRs. Figure 4 shows that 40% of α6β2β3 and 60% of α6β4β3 AChRs precipitated by mAb 338 could be adsorbed by mAb 210 coupled to agarose. This probably underestimates the actual percentage of these AChRs, which contain β3 because of the low affinity of mAb 210 for β3 in these α6 AChRs. Because mAb 210 binds efficiently only to native α3, α5, and β3, but to both native and denatured α1, probably both the sequence, and, especially, the conformation of this MIR epitope are important for binding of mAb210 to neuronal AChRs.

Sedimentation of α6* AChRs on Sucrose Gradients. We have observed previously that, when expressed in X.
laevis oocytes, α3β2 αChRs sedimented on sucrose gradients as a uniform 11S component intermediate in size between monopentamers and dipentamers of T. californica electric organ α1 AChRs, whereas α6β2 αChRs assembled efficiently to form epibatidine binding sites within the oocytes, but these sedimented as large amorphous aggregates (Kuryatov et al., 2000). When expressed in HEK cells, the α6β2 combination results in only small amounts of epibatidine binding sites, but most of these are on the cell surface (Fig. 1). Most of these α6β2 AChRs sediment as components larger than 11S (Fig. 5), and substantial amounts pelleted in the centrifuge tube. Monopentamers were not clearly resolved from 11S (Fig. 5), and substantial amounts pelleted in the centri-

golgi apparatus to the cell surface. Incorporation of the from the endoplasmic reticulum and transport through the were pentamers able to pass quality control analysis for exit cell surface (Fig. 1C) suggests that in the membrane most most were pentamers able to pass quality control analysis for exit from the endoplasmic reticulum and transport through the Golgi apparatus to the cell surface. Incorporation of the β5 subunit to form α6β2β3 AChRs not only results in assembly of many more AChRs (Fig. 1) but also most of these sediment as a component that is nearly the size of 9.5S T. californica AChR monopentamers (Fig. 5). Thus, the presence of β3 accessory subunits permits the efficient assembly of stable pentameric AChRs. Both α6β4 and α6β4β3 AChRs expressed in the cell lines sediment as a mixture of components corresponding to monopentamers and larger aggregates (Fig. 5). The larger proportion of aggregates may bias the monopentamer peak to seem to sediment more rapidly than in the case of α6β2β3 AChRs. The formation of aggregates on sucrose gradients that is prominent with α6* AChRs is not observed with α1*, α3β2, or α4β2 AChRs (Kuryatov et al., 2000, 2005).

**Agonist Binding to α6 AChRs.** Figure 6 shows the concentration dependence of [3H]epibatidine binding to all four α6* AChR subtypes. The Km for binding of epibatidine to α6β2 AChRs (0.154 nM) was basically the same as the Km for binding to α6β2β3 AChRs (0.198 nM), α6β4 AChRs (0.162 nM), or α6β4β3 AChRs (0.130 nM). This compares to the Km for binding of epibatidine to human α4β2 AChRs similarly expressed and measured (0.017 nM) (Kuryatov et al., 2005). Thus, the presence of β3 does not change equilibrium binding affinity of α6β2* or α6β4* AChRs for epibatidine. All four α6* AChR subtypes exhibit much lower affinity for epibatidine than do α4β2 AChRs.

Agonists were tested for their ability to inhibit the binding of [3H]epibatidine to fixed cells (Table 2). In general, the

<table>
<thead>
<tr>
<th>Titer of mAb</th>
<th>μmol [3H]epibatidine binding sites/1 mAb</th>
</tr>
</thead>
<tbody>
<tr>
<td>α3β2</td>
<td>0</td>
</tr>
<tr>
<td>α4β2</td>
<td>0</td>
</tr>
<tr>
<td>α6β4</td>
<td>0.09</td>
</tr>
<tr>
<td>α6β2</td>
<td>4.1</td>
</tr>
</tbody>
</table>

**Table 1**

Immunoprecipitation of native [3H]epibatidine-labeled human AChRs by mAbs to α6 subunits.

The cell lines expressing α6β2 AChRs were described previously (Wang et al., 1998; Kuryatov et al., 2005). A 0.5 nM concentration of AChRs and 1.5 nM [3H]epibatidine were used in these assays using triplicate samples.

**Fig. 3.** Reaction of mAbs to α6 and β3 with denatured subunits on blots. A, subunit specificity of the mAbs was demonstrated by dot blot assays using bacterially expressed human AChR subunit constructs. Reaction is compared with that of antiserum to each of the subunit constructs to demonstrate equal loading of the subunits and thus the high specificity of the mAbs. B, specificity of the mAbs was further evaluated using Western blots of equal amounts of AChRs from HEK cell lines transfected with human α6β4β3, α6β4α5, or α4β2 AChRs. The mAbs reacted strongly only with α6 subunits and not at all with the other subunits present. C, extent of expression of α6 subunits in the four α6* AChR cell lines was compared using an equal amount of protein from each line and mAb 349. mAbs were used at a 1/1000 dilution and 125I-goat anti-
mouse IgG purified antibodies were used at 2 nM. D, reaction of mAb 353 with chimeras (Kuryatov et al., 2000) consisting of the extracellular domains of α3 or α6 in combination with the remainder of the other of these sub-
units on Western blots. The transmembrane orientation of the epitopes of the α6 mAbs was determined using Western blots of equal amounts of chimeric AChRs from X. laevis oocytes injected with 25 ng per subunit of cRNA for the subunit combinations of α3/6β2 or α6/ 3β2. All six mAbs to α6 reacted strongly with chimeric α3β6 subunits and not at all with α6β3 subunits. Only the Western blot of mAb 353 is shown.
β2-containing α6* AChRs exhibited higher affinities for agonists. Cytisine discriminated by more than 7-fold in affinity between α6β2* and α6β4* AChRs. The affinity for nicotine is not significantly altered by the presence or absence of β3 subunits. Both equilibrium binding studies of epibatidine (Fig. 6) and competitive binding studies with nicotine and other ligands (Table 2) indicate that the presence of β3 does not alter the ACh binding site or its affinity for nicotine. This is not surprising, because β3 assembles in the accessory position and is not part of an ACh binding site.

**β3 Greatly Increased Sensitivity of α6* AChRs to Nicotine-Induced Up-Regulation.** Table 3 shows that the presence of β3 increased the sensitivity to nicotine-induced up-regulation of α6β2β3 by 11-fold compared with α6β2 AChRs and of α6β4β3 AChRs by 6.6-fold compared with α6β4 AChRs. The binding data of Fig. 6 and Table 2 show that the presence of β3 does not alter the ACh binding sites and greatly increases affinity for nicotine. So, how might β3 have such a large effect on nicotine-induced up-regulation? Nicotine probably acts on α6* AChRs as a molecular chaperone, as it does on α4β2 AChRs (Kuryatov et al., 2005; Sallette et al., 2005). Binding of nicotine to α6β2α6β2 or α6β4α6β4 assembly intermediates could produce activated or desensitized conformations that would assemble more efficiently with β3 than β2 or β4 subunits in the accessory position in a final assembly step to form mature pentamers. The greater AChR expression observed with β3-containing AChRs in the absence of nicotine (Fig. 1) shows that β3 promotes assembly of mature AChRs. On the other hand, nicotine could act as a molecular chaperone on α6β2β3 or α6β4β3 assembly intermediates, and the presence of β3 could promote conformational changes to the active or desensitized conformations, which assemble more efficiently. The accessory subunit α5 influences the sensitivity to activation and desensitization of α3* AChRs (Gerzanich et al., 1998).

The EC_{50} for up-regulation by nicotine of α6β2 AChRs (9.8 μM) indicates that at the 0.1 to 0.2 μM concentrations of nicotine sustained in the sera of cigarette smokers (Benowitz, 1996), up-regulation of this subtype would be negligible. By contrast, the EC_{50} for α6β2β3 (0.89 μM) reveals that the presence of β3 confers an order of magnitude more sensitivity to nicotine-induced up-regulation, sufficient to suggest that some up-regulation might occur in a smoker. Still, the sensitivity is much less than that of human α3β2 AChRs expressed in tsA201 HEK cells (EC_{50} = 0.039 μM) (Kuryatov et al., 2005), an AChR subtype that has much higher affinity for nicotine (K_{D} = 0.0028 μM). β3 also increases the sensitivity to nicotine-induced up-regulation of α6β4β3 AChRs from EC_{50} = 3.55 μM for α6β4 AChRs to EC_{50} = 0.54 μM for α6β4β3 AChRs.

Unlike human α3 AChRs expressed in HEK cell lines, where only β2-containing but not β4 containing AChRs are subject to nicotine-induced up-regulation (Wang et al., 1998), α6* AChRs containing either β2 or β4 subunits are sensitive to nicotine-induced up-regulation. The extent of up-regulation is greater for α6β2β3AChRs than for α6β4β3 AChRs, presumably reflecting the lower baseline assembly efficiency of β2 than β4 subunits (Wang et al., 1998; Sallette et al., 2004).

**Culture at 29°C in Combination with Nicotine Dramatically Up-Regulates Expression of α6β2 AChRs.** Cooper et al. (1999) initially observed that culture at 30°C increased expression of α4β2 AChRs and proposed that this resulted from increased assembly and/or slower turnover. The low amount of α6 subunits in the α6β2 cell line by contrast with the large amount after transfection of this line with β3 (Fig. 3C) suggests that unassembled α6 and α6β2 AChRs are unstable and that transfection with β3 promotes assembly and/or stabilizes the resulting AChRs. The large amount of α6 in the other lines shows that, if the AChRs are stabilized by the right subunit combination and ambient conditions, the α6 expression vector can result in substantial amounts of AChRs. Culture at 29°C increased the amount of α6β2 AChRs to that obtained in the presence of β3, and it greatly increased the extent and sensitivity to nicotine-induced up-regulation, somewhat exceeding the effect of β3 on the amount of AChR (Fig. 7). α6β4 AChRs were expressed at a higher level than α6β2 at 37°C, so the effects of culture at 29°C were substantial but less. In the presence of β3, there was little effect on nicotine-induced up-regulation of α6β2β3 AChRs and virtually none on α6β4β3 AChRs. These results are consistent with the idea that low temperature greatly increases the stability of α6β2 assembly intermediates and AChRs, and it increases to a lesser extent the stability of the intrinsically more stable α6β4 assembly intermediates and AChRs, while also promoting their assembly synergistically with the pharmacological chaperone effects of nicotine.

The differences in α6β2 expression between HEK cells shown here and X. laevis oocytes (Kuryatov et al., 2000) demonstrate the importance of cell-specific factors on AChR assembly, and they suggest the possibility that in some cell
subunits were made to aid in the characterization of AChR subtypes. Even more complex with brain neurons containing small amounts of complex mixtures of AChR subtypes. Even more complex AChR subtypes such as α6β2β3, which have been identified in brain and retina (Zoli et al., 2002; Champaiaux et al., 2003; Gotti et al., 2005a,b), will also need to be studied in transfected cell lines. α6 AChRs are potential drug targets, for example, in Parkinson’s disease (Quik and McIntosh, 2006).

Host cell type influences the expression of AChRs, presumably as a reflection of differences the complement of chaperone proteins and enzymes for post-translational modification. For example, the chaperone protein Ric-3 is expressed in the human neuroblastoma cell line SH-SY5Y, which endogenously expresses α7 AChRs, but is not expressed in tsA201 HEK cells, which efficiently express transfected α7 AChRs only after cotransfection with Ric-3 (Landsdell et al., 2005; Williams et al., 2005). α6 AChRs have only been reported in aminergic neurons, which may contain particular chaperones for the assembly and transport of α6 AChRs.

Expression of α6β2 in X. laevis oocytes results in the formation of large amounts of epibatidine binding sites but no mature pentameric AChRs on the cell surface (Kuryatov et al., 2000). Instead, α6 and β2 subunits form amorphous intracellular aggregates. In HEK cells only small amounts of α6β2 AChRs are made, but a large proportion are on the cell surface. α6 is closely related in sequence to α3 (Lindstrom, 2000; Le Novere et al., 2002). α3β2 forms functional AChRs in oocytes (Gerzanich et al., 1998). In tsA201 HEK cell lines, α3β2 expresses less well than does α3β4 (Wang et al., 1998), resembling the relationship between α6β2 and α6β4. In HEK cell lines, α3β2 is greatly up-regulated by nicotine but human α3β4 is not (Wang et al., 1998). α6β4 is up-regulated by nicotine. Thus, there are both cell type and subunit-specific factors that influence expression.

Culture at 29°C dramatically increases the expression of α6β2 and its sensitivity to up-regulation by nicotine but has a smaller effect on α6β4 (that is intrinsically expressed at a higher level). The low temperature apparently greatly stabilizes α6β2 AChRs or their assembly intermediates, permitting the accumulation of large amounts under the influence of nicotine. Nicotine probably acts as a pharmacological chaperone (Kuryatov et al., 2005; Corringer et al., 2006). In HEK cells, nicotine dramatically increases the amount of α3β2 AChRs (22-fold) without causing a dramatic increase (perhaps 2-fold) in the amount of α3 subunits on Western blots (Wang et al., 1998), indicating that, as in an α4β2 line

Discussion

Four subtypes of human α6 AChRs (α6β2, α6β2β3, α6β4, and α6β4β3) were stably expressed in human tsA201 HEK cell lines, and six mAbs to human α6 and one mAb to human β3 subunits were made to aid in the characterization of α6 AChRs. These mAbs were found to be directed at sequences C-terminal of the extracellular domain. These lines will permit more detailed studies of these AChR subtypes than is possible with brain neurons containing small amounts of complex mixtures of AChR subtypes. Even more complex α6 AChR subtypes such as α6β2β3, which have been identified in brain and retina (Zoli et al., 2002; Champaiaux et al., 2003; Gotti et al., 2005a,b), will also need to be studied in transfected cell lines. α6 AChRs are potential drug targets, for example, in Parkinson’s disease (Quik and McIntosh, 2006).

Host cell type influences the expression of AChRs, presumably as a reflection of differences the complement of chaperone proteins and enzymes for post-translational modification. For example, the chaperone protein Ric-3 is expressed in the human neuroblastoma cell line SH-SY5Y, which endogenously expresses α7 AChRs, but is not expressed in tsA201 HEK cells, which efficiently express transfected α7 AChRs only after cotransfection with Ric-3 (Landsdell et al., 2005; Williams et al., 2005). α6 AChRs have only been reported in aminergic neurons, which may contain particular chaperones for the assembly and transport of α6 AChRs.

Expression of α6β2 in X. laevis oocytes results in the formation of large amounts of epibatidine binding sites but no mature pentameric AChRs on the cell surface (Kuryatov et al., 2000). Instead, α6 and β2 subunits form amorphous intracellular aggregates. In HEK cells only small amounts of α6β2 AChRs are made, but a large proportion are on the cell surface. α6 is closely related in sequence to α3 (Lindstrom, 2000; Le Novere et al., 2002). α3β2 forms functional AChRs in oocytes (Gerzanich et al., 1998). In tsA201 HEK cell lines, α3β2 expresses less well than does α3β4 (Wang et al., 1998), resembling the relationship between α6β2 and α6β4. In HEK cell lines, α3β2 is greatly up-regulated by nicotine but human α3β4 is not (Wang et al., 1998). α6β4 is up-regulated by nicotine. Thus, there are both cell type and subunit-specific factors that influence expression.

Culture at 29°C dramatically increases the expression of α6β2 and its sensitivity to up-regulation by nicotine but has a smaller effect on α6β4 (that is intrinsically expressed at a higher level). The low temperature apparently greatly stabilizes α6β2 AChRs or their assembly intermediates, permitting the accumulation of large amounts under the influence of nicotine. Nicotine probably acts as a pharmacological chaperone (Kuryatov et al., 2005; Corringer et al., 2006). In HEK cells, nicotine dramatically increases the amount of α3β2 AChRs (22-fold) without causing a dramatic increase (perhaps 2-fold) in the amount of α3 subunits on Western blots (Wang et al., 1998), indicating that, as in an α4β2 line

Fig. 5. Sucrose gradient sedimentation of α6 AChRs. Sedimentation on SW41 5 to 20% sucrose gradients used T. californica AChRs as internal standards. T. californica AChRs were immunosolated from gradient fractions on wells coated with mAb 210 and then labeled with 125I-α-bungarotoxin. Arrows indicate the positions of the peaks corresponding to the 9.5S monomers and 13S dimers of T. californica AChRs. α6β2 and α6β2β3 AChRs were isolated on microwells coated with mAb 295 to β2 subunits. α6β4 and α6β4β3 AChRs were isolated on microwells coated with mAb 338 to α6 subunits. Isolated α6 AChRs were labeled with [3H]epibatidine. mAb 338 to α6 and mAb 337 to β4 subunits (Nelson et al., 2001) were equally effective when coated on microwells at adsorbing α6 and α6β4β3 AChRs. However, mAb 338 was much less effective at adsorbing α6β2 and α6β2β3 AChRs. Thus, mAb 295-coated wells were used. The epitope for mAb 338 is probably near the subunit interface and influenced by the β subunit present. The sucrose gradients shown were representative of several similar gradients analyzed.
(Kuryatov et al., 2005), there are large pools of unassembled α3 subunits present. By contrast, Western blots of α6β2 reveal that only small amounts of α6 are present, even though transfection of this line with β3 results in much larger amounts of α6, and parallel α6β4 and α6β4β3 lines contain much more α6. Thus, unassembled α6 as well as α6β2 AChRs must be relatively unstable. Using chimeras between α6 and α3 or α4 subunits, the part of the α6 subunit that limits expression of mature AChRs with β2 in X. laevis oocytes was mapped to sequences C-terminal of the extracellular domain of α6 (Kuryatov et al., 2000). In α6* AChR-expressing neurons, there may be chaperones that have effects similar to culture at 29°C in promoting the assembly and stability of α6β2 AChRs.

The presence of β3 in the accessory position greatly increased expression of α6β2 and α6β4, increased sensitivity to up-regulation by nicotine, and negated any additional effect of culture at 29°C. In these respects, the effects of β3 were more dramatic than the effects of α5 on α3 AChRs (Gerzanich et al., 1998; Wang et al., 1998). The effects of temperature, nicotine, and subunit composition suggest that regulation of AChR expression in these cell lines occurs primarily at the post-translational level. Studies of the amount of AChR α4 and β2 subunit protein in the brains of AChR subunit knockout mice similarly demonstrate that in brain, the regulation of AChR expression also occurs primarily at the post-translational level (Whiteaker et al., 2006). In X. laevis oocytes (Peng et al., 1994), HEK cells (Kuryatov et al., 2005), and rodent brain (Flores et al., 1992), nicotine-induced up-regulation of α4β2 AChRs occurs by post-translational mechanisms.

The complete aggregation of α6β2 AChRs expressed in X. laevis oocytes (Kuryatov et al., 2000) and extensive aggregation of α6* AChR subtypes expressed in HEK cells suggest that this reflects a particular property of α6 subunits. The detergent Triton X-100 used for solubilization may partially

![Graphs showing concentration dependence of binding of [3H]epibatidine by cell lines.](image)

**Fig. 6.** Concentration dependence of binding of [3H]epibatidine by cell lines. α6β2* AChR cells were fixed after up-regulation overnight with nicotine (100 μM) or 10 μM in the case of α6β2(3) to provide convenient amounts of AChRs for assay. α6β4 and α6β4β3 cells did not require up-regulation. Binding was assayed using the indicated concentrations of [3H]epibatidine. Background binding, assayed in the presence of 1 mM nicotine, was subtracted. The values shown are mean ± S.E.M. for quadruplicate assays.

<table>
<thead>
<tr>
<th>Subtype</th>
<th>ACh</th>
<th>Nicotine</th>
<th>DMPP</th>
<th>Cytisine</th>
</tr>
</thead>
<tbody>
<tr>
<td>α6β2</td>
<td>2.82 ± 0.04</td>
<td>0.72 ± 0.06</td>
<td>0.51 ± 0.01</td>
<td>0.25 ± 0.01</td>
</tr>
<tr>
<td>α6β2β3</td>
<td>1.52 ± 0.01</td>
<td>0.40 ± 0.05</td>
<td>0.93 ± 0.06</td>
<td>0.25 ± 0.01</td>
</tr>
<tr>
<td>α6β4</td>
<td>6.30 ± 0.64</td>
<td>1.79 ± 0.17</td>
<td>1.32 ± 0.22</td>
<td>1.92 ± 0.28</td>
</tr>
<tr>
<td>α6β4β3</td>
<td>6.88 ± 0.24</td>
<td>1.39 ± 0.03</td>
<td>2.08 ± 0.12</td>
<td>4.48 ± 0.27</td>
</tr>
</tbody>
</table>

**TABLE 2**

Relative affinities of α6* AChR subtypes for agonists. Serial dilutions of agonists were applied with [3H]epibatidine at 2 nM to cells fixed with formalin on Costar 96-well white with clear-bottom plates. The concentration-response curves were fitted using a nonlinear least-squares error curve fit method (KaleidaGraph; Abelbeck/Synergy Software, Reading, PA) to the Hill equation $I(x) = \frac{L_{max}c^{n}x^{n}}{IC_{50}^{n} + x^{n}}$. Values are shown ± S.E.M.

DMPP, 1,1-dimethyl-4-phenylpiperazinium iodide.
dissociate some α6 AChR subtypes and subsequent reaggregation might account for the sedimentation properties observed. The presence of β3 greatly increased the proportion of monopentamers in α6β2β3 AChRs compared with α6β2 AChRs, perhaps by stabilizing them against dissociation. It will be interesting to determine whether substitution of one of the two α6 subunits in an AChR pentamer by an α4 or α3 subunit to produce the most abundant and complex subtypes of brain α6 AChRs might reduce or eliminate aggregation of the resulting AChRs, reflecting a stabilizing influence on pentamers.

The presence of β3 subunits increased sensitivity to up-regulation by nicotine of α6+ AChRs to the range where the 0.1 to 0.2 μM concentration of nicotine sustained in the sera of cigarette smokers (Benowitz, 1996) would be expected to cause some up-regulation of these α6+ AChR subtypes in brain. However, these α6+ AChRs are much less sensitive to up-regulation than are α4β2 AChRs (Kuryatov et al., 2005).

Parker et al. (2004) reported selective up-regulation of α6β2 AChRs compared with α4β2 AChRs in rat brain as a result of long-term self-administration of nicotine. On the contrary, reduction in the amount of α6+ AChRs after nicotine treatment in various other ways has been reported in rats, mice, and monkeys (Lai et al., 2005; McCallum et al., 2006; Mugnaini et al., 2006). How can these apparently contradictory results on the ability of nicotine to up-regulate α6+ AChRs be explained? Dopaminergic neurons in the ventral tegmental area of rodents express a mixture of α4, α6, β2, and β3 subunits and preferentially transport α4α6β2β3 to their nerve endings in the striatum but express α4β2 AChRs on the cell bodies (Zoli et al., 2002; Champtiaux et al., 2003; Gotti et al., 2005b; Quik et al., 2005). In primates, α3 subunits are also involved, and there is a lower proportion of αβ2 in the endings. In monkey striatum, 70% of nicotine-evoked dopamine release is mediated by α6β2 and/or α3β2+ AChRs, whereas in rodents α6β2+ AChRs mediate only 30% (Quik and McIntosh, 2006). This complex mixture of AChRs subunits competes for assembly in the endoplasmic reticulum of these neurons. Nicotine acts as a molecular chaperone to promote assembly of AChRs by binding to assembly intermediates (Kuryatov et al., 2005; Sallette et al., 2005; Corringer et al., 2006). The mean plasma nicotine concentration in monkeys given nicotine in their drinking water was 51 nM (McCallum et al., 2006). This would efficiently promote up-regulation of human α4β2 AChRs expressed in HEK cells (EC50 = 35 nM; Kuryatov et al., 2005), but it would have little effect on α6β2β3 AChRs (EC50 = 890 nM). If the amount of β2 subunits were limiting, at low nicotine concentrations, increased assembly of α4β2 AChRs could decrease assembly of α6β2β3 AChRs by depleting the pool of β2 subunits. Nicotine-induced slowing of mature AChR destruction (Kuryatov et al., 2005) could also up-regulate AChRs in nerve endings as well as on the cell body. Up-regulation by this

![Graphs](image-url)

**Fig. 7.** Culture at 29°C greatly increased expression and sensitivity to nicotine-induced up-regulation of α6β2 and α6β4 AChRs. The indicated cultures were shifted to 29°C for the 12- to 15-h period during which nicotine was applied. Then, cells were fixed before measuring binding of [3H]epibatidine applied at 2 nM. The values shown are mean ± S.E.M. for quadruplicate assays.

<table>
<thead>
<tr>
<th>AChR</th>
<th>EC50 (μM)</th>
<th>Bmax (fmol/well)</th>
</tr>
</thead>
<tbody>
<tr>
<td>α6β2</td>
<td>9.84 ± 0.03</td>
<td>1.13 ± 0.08</td>
</tr>
<tr>
<td>α6β2β3</td>
<td>0.89 ± 0.29</td>
<td>4.56 ± 0.75</td>
</tr>
<tr>
<td>α6β4</td>
<td>3.55 ± 0.62</td>
<td>21.3 ± 1.7</td>
</tr>
<tr>
<td>α6β4β3</td>
<td>0.54 ± 0.13</td>
<td>42.0 ± 4.1</td>
</tr>
</tbody>
</table>
mechanism might also selectively affect high affinity α4β2* AChRs. Most nicotine-induced brain AChR up-regulation is of highly sensitive α4β2 AChRs (Flore et al., 1992). Autonomic ganglia express a mixture of α3, β2, β4, and α5 subunits but preferentially assemble α3β4 AChRs (Davila-Garcia et al., 2003; Nguyen et al., 2003). The nicotine concentrations obtained in vivo result in negligible up-regulation of the less sensitive α3* AChRs.

The large increase in amount of α6* AChRs as well as their sensitivity to nicotine-induced up-regulation that results from the β3 subunit is consistent with the hypothesis that assembly of the β3 subunit in the accessory position is the final step in assembly of mature AChRs. The β3 subunit seems to preferentially assemble in the accessory position over β2 or β4 to result in larger amounts of AChRs. β3-containing α6 AChRs did not show increased affinity for nicotine. The increased sensitivity to up-regulation by nicotine in the presence of β3 could result from assembly intermediates such as α6β2 or α6β2αβ2, assuming a nicotine-induced desensitized conformation that more efficiently assembles with β3. On the other hand, assembly intermediates incorporating β3, such as β3α6β2, could more efficiently assemble a nicotine-induced conformation that assembles more efficiently.

References


